Patient recruitment has begun for MOVE-IT - the first randomised controlled trial evaluating model-informed precision dosing (MIPD) for vedolizumab and ustekinumab in inflammatory bowel disease. Our working group is a collaboration partner in this multicenter study coordinated by Odense University Hospital, Denmark. The trial investigates whether personalised, model-based dosing can provide equal efficacy and improved cost-effectiveness compared with symptom-based management.